苯磺唑酮辅助治疗痛风的临床疗效研究  

Study on Clinical Efficacy of Sulfinpyrazone Adjuvant Treatment to Gout

作　　者：魏会英[1] 

机构地区：[1]黑龙江省绥芬河市妇幼保健院,157300

出　　处：《中国继续医学教育》2015年第7期215-216,共2页China Continuing Medical Education

摘　　要：目的探索苯磺唑酮(苯磺保泰松)辅助治疗痛风的临床疗效,为以后痛风的药物内科治疗开辟新的用药方案。方法随机筛选2014年1月至今在我院进行诊疗的800例痛风患者,然后根据随机分组的方法将所抽取的患者平均分为实验组和对照组。结果实验组患者的总有效率明显要好与对照组,并且两组患者的治疗效果以及用药过程中临床症状经对比分析后显示,差异具有统计学意义(P<0.05)。结论常规应用药物联合苯磺保泰松辅助性治疗,可有效的提高痛风的症状缓解率并且获得不错的临床诊疗效果。Objective To explore the clinical efficacy of sulfinpyrazone adjuvant treatment to gout, so as to establish new regimen for gout medical treatment. Methods 800 patients with gout from January 2014 up to now in our hospital were randomly selected into experimental and control group. Results The total efficiency of the experimental group were significantly better than the control group. The clinical effect and symptoms between two groups were compared, the difference between two groups were statistically significant（P〈0.05）. Conclusion Routine therapy and sulfinpyrazone

关 键 词：辅助性治疗 苯磺保泰松 痛风 药物疗效 

分 类 号：R589.7[医药卫生—内分泌]